PSA testing and early detection may prevent up to 17,000 cases of metastatic prostate cancer a year, a new study suggests.
“Yes, there are trade-offs associated with the PSA test and many factors influence the disease outcome,” says Edward M. Messing, chair of urology at the University of Rochester Medical Center.
“And yet our data are very clear: not doing the PSA test will result in many men presenting with far more advanced prostate cancer. And almost all men with metastasis at diagnosis will die from prostate cancer.”
Full story at Futurity.
More research news from top universities.
Photo credit: Fotolia